Medtech’s 2026 Playbook: Buy Into Growth, Sell Out Of Slower Assets
Two deals announced in recent weeks capture the twin forces reshaping medtech in 2026: Pacira selling the rights to a device it was still calling a growth driver weeks earlier, and VB Spine quietly assembling a navigation platform piece by piece.
Medtech Insight - August 24, 2026

Hansa Eyes US Listing Ahead of FDA Idefirix Verdict
The Swedish group has filed paperwork for a potential US NASDAQ IPO which could broaden access to investors as it prepares for a regulatory decision and possible launch of its kidney transplant therapy before the end of the year.
Scrip - August 24, 2026

The New Pharma CIO: Six Technology Leaders On How The Job Is Changing
From AI and data to drug development and workforce transformation, pharma's technology chiefs are taking on a much broader strategic role. We asked six CIOs what that means for their jobs – and where the role is heading next.
In Vivo - August 24, 2026

Pipeline Watch: Two Approvals And Four Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - August 24, 2026

IGI CEO On The Firm’s ‘Unique’ Multispecific For Solid Tumors, Immunotherapy Over ADCs
Ichnos Glenmark Innovation CEO Dr Lida Pacaud talks about the firm's first-in-class multispecific immune cells activator for solid tumors that takes a distinct approach on NK cell engagement and why she believes immunotherapy holds far greater power to transform cancer treatment than ADCs.
Scrip - August 24, 2026

Aeon Bolsters Botox Biosimilar Package With Expanded Data
Aeon Biopharma has reported expanded data that it says further confirm the similarity of its ABP-450 proposed biosimilar to Botox.
Generics Bulletin - August 24, 2026

Teva Secures A 2036 US Launch Date For Its Generic To Aurinia’s Lupkynis
Teva has settled patent infringement litigation with Aurinia Pharmaceuticals over Lupkynis (voclosporin), securing the right to launch its generic version one year before the two disputed dosing method patents expire in December 2037.
Generics Bulletin - August 24, 2026

‘We Expect To Be First To Market For That’: Organon’s Azzinaro On Taking Pole Position In Pertuzumab
Organon’s global commercial lead for biosimilars, Joe Azzinaro, talks about the significance of the firm’s first-mover advantage on pertuzumab, as well as how its portfolio of other biosimilars is competing in crowded global markets.
Generics Bulletin - August 24, 2026

Upsher-Smith Joins Crowded Copaxone Generic Market
Upsher-Smith has entered the US glatiramer acetate market with two AP-rated strengths, adding another complex generic to its growing portfolio while joining an established field of Copaxone competitors.
Generics Bulletin - August 24, 2026

Roche Adds A Fourth Obesity Mechanism With Hanmi Deal
Roche pays $190m up front, up to $2.3bn total, for Hanmi's muscle-sparing obesity candidate.
Scrip - August 24, 2026

Notified Body Closures Signal A Difficult Transition Period For EU Regulation
Experts say lowered demand, staff shortages, and changes to MDR and IVDR are forcing a realignment of the notified body sector.
Medtech Insight - August 24, 2026

FDA Consumer Health Advisory: Commissioner Nomination Wins Industry Support
What's happening, why it matters and what's next at FDA. This edition explores the nomination of Heidi Overton as commissioner, success in curbing OTC contaminations and the withdrawal of marketing claims by Quanovate following P&G challenge.
HBW Insight - August 24, 2026

FastWave’s Artero Enters Pivotal Trial, Betting Speed And Simplicity Can Crack A Crowding IVL Market
With FDA clearance for its SPARC pivotal trial, CEO Scott Nelson is betting that a physician-first design—circumferential energy, a faster pulse, and a workflow built for office-based labs—can set the Artero electric IVL system apart from a field of deep-pocketed rivals.
Medtech Insight - August 24, 2026

FDA Device Recalls: Records Jumped 28% In 2026, But Distinct Events Barely Moved
A 28% jump in FDA device recall records in 2026 looks alarming - unless you count distinct events, which rose just 2.5%, while Class I events actually fell 16%. Two firms, Medline and Olympus, and the way kitted products are counted explain most of the surge.
Medtech Insight - August 24, 2026

Three Strategies US Device Makers Are Using To Stem Staff Burnout And Turnover
Corporate medtech industry employee engagement has slipped to a decade low. In 2026, leading medtech firms abandoned generic HR programs in favor of mission-linked leadership, adaptive capacity building and authentic manager communication to stem staff burnout and turnover.
In Vivo - August 24, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: melanoma win for Moderna's mRNA candidate; lung cancer victory for Enhertu; measuring industry R&D productivity; Enveda's post-GLP-1 contender; and the factors behind China's rise.
Scrip - August 24, 2026

Pinworm Treatment Marketer Scratches Claims For Efficacy Against Other Intestinal Parasites
Wellspring Meds discontinues express claims for Pin Rid challenged by PinWorm marketer Reese Consumer Health but maintains claims to also treat roundworms, hookworms, whipworms, threadworms and tapeworms are accurate.
HBW Insight - August 24, 2026